The importance of metabolism for cancer development and progression has been increasingly recognized over the past decade. Cancer cells undergo drastic alternations of metabolism, including metabolism of glucose and lipid, and oxidative responses. These processes are highly regulated by AMPK and p53. AMPK is activated by LKB1 and AMP/ADP in response to bio-energy shortage to coordinate metabolism, cell growth, apoptosis and autophagy by phosphorylating its target proteins. Also, the tumor suppressor p53 can be activated by this type of stress to confine metabolic pathways, which favor tumor growth, and to turn on cellular pathways that lead to cell growth arrest and apoptosis by inducing a variety of genes important for these functions. The anti-tumor function of p53 is tightly regulated by its two physiological antagonists MDM2 and MDMX, which form a complex to act as a negative feedback regulator of p53. Hence, blocking this feedback regulation is the key for cellular stresses to activate p53. For instance, ribosomal stress (RS) leads to p53 activation by inducing the interaction of ribosomal proteins L11 and L5 with MDM2 and restraining the latter's activity toward p53, but defect of this interaction in MDM2C305F mice impairs this pathway. Interestingly, AMPK can act as an upstream regulator of p53 upon metabolic stress by phosphorylating MDMX at Ser342, leading to inactivation of MDMX by inducing its binding to 14-3-3, consequently activating p53. Hence, our studies suggest that MDMX may function as a crucial player under metabolic stress. Also our preliminary studies using MDM2C305F and MDMX3SA double knock-in mice showed that the double impairments of the MDM2-MDMX-p53 pathways cause significant defects of lipid and glucose metabolisms in livers upon fasting. Thus, we hypothesize that the metabolic stress-AMPK-MDMX/RS-MDM2-p53 pathways may play an important role in regulation of metabolism in both normal and cancer cells upon metabolic stress. We will test this hypothesis by addressing three specific aims. 1. To elucidate mechanisms underlying the AMPK inhibition of MDMX activity toward p53 in response to metabolic stress. A) Does S342 phosphorylation by AMPK induce nuclear localization and degradation of MDMX? B) Does S342 phosphorylation by AMPK affect the formation of the MDMX-MDM2 complex? C) Does S342 phosphorylation by AMPK induce 14-3-3-binding to S367 of MDMX? 2. To determine if the AMPK-MDMX/RS-MDM2-p53 pathways play a role in regulation of metabolism in cells and mice. A. To determine if dual defects of the MDMX-MDM2-p53 pathway impair energy metabolism under physiological and stress conditions. B. To illustrate new p53 responsive genes important for regulation of lipid and glucose metabolism by the AMPK-MDMX/RS-MDM2-p53 pathways. 3. To determine if dual defects of the AMPK-MDMX/RS-MDM2-p53 pathways accelerate tumorigenesis in two mouse tumor model systems. Completing these studies would offer molecular insight into how lipid and glucose metabolism is controlled by this pathway, and also reveal new molecule targets for future anti-cancer drug discovery.

Public Health Relevance

Aberrant alterations of metabolisms in cancer cells are crucial for cancer development and progression, but the underlying molecular pathways or mechanisms remain incompletely understood. Studies by others and us reveal the AMPK-MDMX-p53 pathway as one such important pathway that senses metabolic stress, such as low nutrients or low oxygen supplies, leading to the elevation of the tumor suppressor p53 activity via activation of AMPK, an energy sensing protein kinase. Hence, the proposed studies in this application are aimed to understand how its alterations might contribute to the development of cancer, and completing the proposed studies would not only shed light onto the molecular events accounting for cancer mechanisms, but also offer information for identification of new molecules as potential anti-cancer drug targets in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA127724-09
Application #
9333196
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Watson, Joanna M
Project Start
2007-04-01
Project End
2020-08-31
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
9
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Tulane University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
053785812
City
New Orleans
State
LA
Country
United States
Zip Code
70118
Cao, Bo; Fang, Ziling; Liao, Peng et al. (2017) Cancer-mutated ribosome protein L22 (RPL22/eL22) suppresses cancer cell survival by blocking p53-MDM2 circuit. Oncotarget 8:90651-90661
Zhang, Yiwei; Zeng, Shelya X; Hao, Qian et al. (2017) Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner. Dev Biol 423:34-45
Zhou, Xiang; Cao, Bo; Lu, Hua (2017) Negative auto-regulators trap p53 in their web. J Mol Cell Biol 9:62-68
Nguyen, Daniel; Liao, Wenjuan; Zeng, Shelya X et al. (2017) Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther 178:92-108
Zhou, Xiang; Hao, Qian; Liao, Peng et al. (2016) Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator. Elife 5:
Chao, Tengfei; Zhou, Xiang; Cao, Bo et al. (2016) Pleckstrin homology domain-containing protein PHLDB3 supports cancer growth via a negative feedback loop involving p53. Nat Commun 7:13755
Cao, Bo; Wang, Kebing; Liao, Jun-Ming et al. (2016) Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation. Elife 5:
Liao, Jun-Ming; Cao, Bo; Deng, Jun et al. (2016) TFIIS.h, a new target of p53, regulates transcription efficiency of pro-apoptotic bax gene. Sci Rep 6:23542
Hughes, Scott J; Antoshchenko, Tetyana; Chen, Yun et al. (2016) Probing the ATP Site of GRP78 with Nucleotide Triphosphate Analogs. PLoS One 11:e0154862
Shi, Chao; Huang, Dengliang; Lu, Nonghua et al. (2016) Aberrantly activated Gli2-KIF20A axis is crucial for growth of hepatocellular carcinoma and predicts poor prognosis. Oncotarget 7:26206-19

Showing the most recent 10 out of 31 publications